Seemann, Jens
Traschütz, Andreas
Ilg, Winfried http://orcid.org/0000-0002-1537-1336
Synofzik, Matthis
Funding for this research was provided by:
IMPRS-IS
Else Kröner-Fresenius-Stiftung (Medical Scientist programme ‘ClinbrAIn’, Clinician Scientist programme "PRECISE.net")
Universitätsklinikum Tübingen
Article History
Received: 30 May 2023
Revised: 5 July 2023
Accepted: 6 July 2023
First Online: 13 July 2023
Declarations
:
: All authors declare no conflict of interest concerning the research related to the manuscript. Prof. Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, and AviadoBio, all unrelated to the present manuscript. Dr. Ilg received consultancy honoraria by Ionis Pharmaceuticals, unrelated to the present manuscript.
: This single-subject treatment was applied as part of an “individual trial of therapy” under a structured named patient treatment protocol (German: individueller Heilversuch). No IRB approval is applicable here. However, it has to be (and is) fully aligned with the 1964 Declaration of Helsinki and its later amendments. As requested by the Declaration of Helsinki, such single-subject treatment experiences should be used to generate systematic knowledge (i.e., generalisable knowledge of value beyond the single treated subject), e.g., by systematically documenting and analyzing treatment response features. Also, the patient provided informed oral and written consent in accordance with specific national laws and the ethics standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: All authors had full access to the data in the case report and had final responsibility for the decision to submit for publication.